Dotfix® 2 mg is a medication containing Dotinurad, a selective urate reabsorption inhibitor (SURI) developed by Square Pharmaceuticals Ltd. It is used for the chronic management of hyperuricemia in patients with gout. Dotinurad works by inhibiting the URAT1 transporter in the kidneys, reducing the reabsorption of uric acid, and thereby increasing its excretion in urine. This action helps lower serum uric acid levels, which is beneficial in preventing gout attacks and associated complications.